Clinical Course, Risk Factors and Health Outcome of in patients with COVID-19: An Evidence from COVID-19 Dedicated Mugda Medical College and Hospital in Bangladesh

Authors
Dr Irin Hossain¹, Dr Shah Golam Nabi Tuhin², Dr Ashekur Rahman Mullick³*, Prof. Dr Manzurul Haque Khan⁴, Dr M M Aktaruzzaman⁵, Dr Md. Shafiur Rahman⁶, Dr Md Shahin⁷
¹,³,⁶,⁷National Institute of Preventive and Social Medicine (NIPSOM), Dhaka, Bangladesh
²Mugda Medical College and Hospital, Dhaka, Bangladesh
⁴Directorate General of Health Services (DGHS), Dhaka, Bangladesh
⁵Dhaka Medical College and Hospital, Dhaka, Bangladesh
*Corresponding Author

Abstract
The outbreak of the novel corona virus disease 2019 (COVID-19) began in Wuhan, China in December 2019. Since then, it has rapidly spread around the world. The clinical spectrum of COVID-19 pneumonia ranges from mild to critically ill cases. In this study, we tried to present details of patients admitted to the COVID-19 dedicated Mugda Medical College and Hospital in Dhaka, Bangladesh with laboratory-confirmed COVID-19 and a definite clinical outcome (death or discharge) as of June 30, 2020. We conducted a retro-prospective study of 384 patients admitted with COVID-19. Epidemiological, demographic, clinical, treatment, and outcome data were obtained from patient charts and the hospitals’ admission records using a structured questionnaire. Among them 384 of the PCR confirmed COVID-19 cases had an outcome of death (25.5%), transfer to other facilities (3.1%), discharge through palliative purpose (1.6%) or live discharge (67.2%). Males accounted for 52.9% of the study subjects and 44.4% of the survivors. Survival was significantly higher in females than in males (p ≤0.001). The most common symptoms on admission were fever (21, 70.6%) and cough (229, 59.6%), followed by shortness of breath (200, 52.1%), fatigue (152, 39.6%) and sore throat (141, 36.7%). In-hospital death was higher in patients with diabetes or hypertension. Moving forward, we hope to continue to deliver early and optimal care, limit community transmission, and tying the case fatality to the lower end of the known range.

Keywords: Clinical Course, Risk Factors, Health Outcome, COVID-19 Pandemic.

Introduction
The outbreak of the novel corona virus disease 2019 (COVID-19) began in Wuhan, China in December 2019¹-⁷. Since then, it has rapidly spread around the world²-⁴. The clinical spectrum of COVID-19 pneumonia ranges from mild to critically ill cases³,⁴. Patients with mild disease present with symptoms of fever and cough, followed by sputum production and fatigue⁴. Sepsis, respiratory failure, acute respiratory distress syndrome, heart failure, and septic shock are commonly observed in critically ill patients¹-⁷. However, there are significant differences between Bangladesh, China and the US in population demographics,³ smoking rates,⁴ and prevalence of comorbidities.⁵-⁷

Although the outbreak is likely to have started from a zoonotic transmission event associated with a large seafood market that also traded in live wild
animals, it soon became clear that efficient person-to-person transmission was also occurring\(^1\)\(^-\)\(^7\). The clinical spectrum of SARS-CoV-2 infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness\(^6\)\(^-\)\(^8\), and severe viral pneumonia with respiratory failure and even death, with many patients being hospitalised with pneumonia in Dhaka, Bangladesh\(^9\),\(^10\),\(^11\). To our knowledge, no previous studies have been done among patients with definite outcomes. The estimation of risk factors for severe disease and death in these earlier case series are therefore not very robust. Additionally, details of the clinical and virological course of illness have not yet been well described.

Here, we tried to present details of patients admitted to the COVID-19 dedicated Mugda Medical College and Hospital in Dhaka, Bangladesh with laboratory-confirmed COVID-19 and a definite clinical outcome (death or discharge) as of June 30, 2020.

**Materials and Methodology**

**Study Population, Setting, and Design**

We conducted a retro-prospective study of 384 patients admitted into the Mugda Medical College and Hospital, Dhaka, Bangladesh. All patients who were diagnosed with COVID-19 according to WHO interim guidance\(^12\) were screened, and those who died or were discharged between May 1, 2020 and June 31, 2020, were included in this study.

**Data Collection**

Epidemiological, demographic, clinical, treatment, and outcome data were obtained from patient charts and the hospitals’ admission records using a structured questionnaire which was adopted from Novel Coronavirus (COVID-19 Rapid Version) by Global COVID-19 Clinical Platform which was previously used for same purpose in United Kingdom\(^13\) and China\(^14\). All data were collected by expert physicians and public health specialist.

**Statistical Analysis**

Continuous and categorical variables were presented as median (IQR-interquartile range) and n (%), respectively. We used the \(\chi^2\) test, or Fisher's exact test to compare differences between survivors and non-survivors where appropriate. The level of significance was set at 0.05. SPSS 26.0 was used to analyse the data.

**Results**

During the period May 1, 2020 to June 30, 2020, a total of 443 adult patients were hospitalised in Muger Medical College with COVID-19. Among them 384 of the PCR confirmed COVID-19 cases had an outcome of death (25.5%), transfer to other facilities (3.1%), discharge through palliative purpose (1.6%) or live discharge (67.2%). The median age of the 384 patients was 46·0 (IQR 30·0) years, for non-survivors it was 60.0 (IQR 20.0) years and for survivors 40.0 (IQR 24·0) year (table 1).

Males accounted for 52.9% of the study subjects and 44.4% of the survivors. Survival was significantly higher in females than in males (p ≤0.001). A little more than 15% were smokers and smoking was more prevalent among non-survivors (19.4%) than survivors (13.6%). Comorbidities were present in nearly one third of patients, with diabetes (129, 33.6%) being the most common comorbidity, followed by hypertension (124, 32.3%), chronic kidney disease (53, 13.8%) and bronchial asthma (46, 12.0%) (table 1).

The most common symptoms on admission were fever (21, 70.6%) and cough (229, 59.6%), followed by shortness of breath (200, 52.1%), fatigue (152, 39.6%) and sore throat (141, 36.7%) (table 1).

Total 364 (94.8%) patients received antibiotics, 134 (34.9%) received parenteral anticoagulant (Enoxaparin Sodium), 93 (24.2%) received antimalarial drug (Hydroxychloroquine Sulphate), 16 (4.2%) received antivirals. Systematic corticosteroid (87, 22.7%) and angiotensin II receptor blockers (ARBs) (54, 14.1%) were also used in treatment purpose (table 2).

Among 384 patients about 34 (8.9%) were asymptomatic and in symptomatic patient the median time from illness onset (i.e., before admission) to discharge was 19·0 days (IQR 15·25–22.00), whereas the median time to death was 9.0
days (IQR 6.0–15.0). The median time from hospital admission to discharge alive was 14.0 days (IQR 11.00–17.00), whereas the median time to death was 3.0 days (IQR 1.00–9.00) (table 2).

16 patients required invasive mechanical ventilation, of whom 15 (93.75%) died. Acute respiratory distress syndrome (ARDS) was the most frequently observed complication (93, 24.2%), followed by pneumonia (89, 23.2%), septic shock (37, 9.6%), anaemia (21, 5.5%), and cardiac arrest (19, 4.9%) (table 2).

In-hospital death was higher in patients with diabetes or hypertension (table 2). Age, gender, pregnancy status, chest pain, shortness of breathing, chest in-drawing, altered consciousness, diarrhoea, nausea, necessity of oxygen therapy, ICU support, supportive treatment by prone position and inotropes/vasopressors, treatment by systemic corticosteroids, invasive ventilation was also associated with both survivor and non-survivor patients (table 1, 2).

### Table 1: Demographic and clinical findings of patients on admission

| Variables                  | Total (n=384) | Non-survivor (n=98) | Survivor (n=286) | p value |
|----------------------------|--------------|---------------------|------------------|---------|
| **Age, years**             |              |                     |                  |         |
| 50-69 years                | 139 (36.2%)  | 52 (53.1%)          | 111 (43.0%)      | 0.000   |
| 30-49 years                |              |                     |                  |         |
| **Gender**                 |              |                     |                  |         |
| Female                     | 181 (47.1%)  | 69 (70.4%)          | 112 (40.5%)      | ≤0.001  |
| Male                       | 203 (52.9%)  | 29 (30.0%)          | 116 (40.5%)      |         |
| **Current Smoker**         |              |                     |                  | 0.170   |
| Chronic Cardiac Disease    |              |                     |                  |         |
| 36 (9.4%)                  |              | 16 (16.3%)          | 20 (7.0%)        | 0.006   |
| **Comorbidity**            |              |                     |                  |         |
| HTN                        | 124 (32.3%)  | 55 (56.1%)          | 69 (24.1%)       | ≤0.001  |
| Asthma                     | 46 (12.0%)   | 11 (11.2%)          | 35 (12.2%)       | 0.790   |
| CKD                        | 53 (13.8%)   | 29 (29.6%)          | 24 (8.4%)        | ≤0.001  |
| DM                         | 129 (33.6%)  | 55 (56.1%)          | 74 (25.9%)       | ≤0.001  |
| Others                     | 27 (7.0%)    | 13 (13.3%)          | 11 (4.3%)        | 0.184   |
| **On admission records**   |              |                     |                  |         |
| Respiratory rate >24 breaths per min | 111 (28.9%) | 69 (70.4%) | 42 (14.7%) | ≤0.001 |
| Pulse ≥125 beats per min   | 2 (0.5%)     | 2 (0.5%)            | 0 (0.0%)         | 0.065   |
| Fever (temperature ≥37.3°C)| 165 (43.0%)  | 65 (66.3%)          | 100 (35.0%)      | ≤0.001  |
| Fever                      | 271 (70.6%)  | 72 (73.5%)          | 184 (71.3%)      | 0.211   |
| Cough                      | 229 (59.6%)  | 56 (57.1%)          | 156 (60.5%)      | 0.921   |
| Cough with sputum          | 40 (10.4%)   | 11 (11.2%)          | 24 (9.3%)        | 0.850   |
| Cough with haemoptysis     | 7 (1.8%)     | 3 (3.1%)            | 4 (1.6%)         | 0.998   |
| Sore throat                | 141 (36.7%)  | 39 (39.8%)          | 93 (36.0%)       | 0.830   |
| Runny nose                 | 22 (5.7%)    | 3 (3.1%)            | 17 (6.6%)        | 0.848   |
| Wheezing                   | 24 (6.3%)    | 14 (14.3%)          | 9 (3.5%)         | 0.554   |
| Chest pain                 | 52 (13.5%)   | 22 (22.4%)          | 21 (8.1%)        | 0.003   |
| Muscle ache                | 68 (17.7%)   | 20 (20.4%)          | 40 (15.5%)       | 0.493   |
| Joint pain                 | 45 (11.7%)   | 9 (9.2%)            | 33 (12.8%)       | 0.854   |
| Fatigue                    | 152 (39.6%)  | 50 (51.0%)          | 92 (35.7%)       | 0.105   |
| Shortness of breath        | 200 (52.1%)  | 90 (91.8%)          | 93 (36.0%)       | 0.000   |
| Inability to walk          | 88 (22.9%)   | 55 (56.1%)          | 29 (11.2%)       | 0.000   |
| Chest in-drawing           | 66 (17.2%)   | 48 (49.0%)          | 17 (6.6%)        | 0.000   |
| Headache                   | 58 (15.1%)   | 7 (7.1%)            | 44 (17.1%)       | 0.257   |
| Altered consciousness      | 50 (13.0%)   | 31 (31.6%)          | 16 (6.2%)        | 0.000   |
| Abdominal pain             | 31 (8.1%)    | 4 (4.1%)            | 26 (10.1%)       | 0.031   |
| Nausea/Vomiting            | 70 (18.2%)   | 20 (20.4%)          | 46 (17.8%)       | 0.000   |
| Diarrhoea                  | 56 (14.6%)   | 14 (14.3%)          | 40 (15.5%)       | 0.000   |
Table 2: Treatments, complications and outcomes

| Variables                        | Total n=384 | Non-survivor n=98 (25.5) | Survivor n=286 (74.5) | p value |
|----------------------------------|-------------|--------------------------|------------------------|---------|
| Treatments                       |             |                          |                        |         |
| Oral fluids                      | 82 (21.4)   | 14 (14.3)                | 68 (26.4)              | 0.072   |
| Inter-venous fluid               | 47 (12.2)   | 21 (21.4)                | 24 (9.3)               | 0.148   |
| Antiviral drugs                  | 16 (4.2)    | 8 (8.2)                  | 7 (2.7)                | 0.422   |
| Antibiotic drugs                 | 364 (94.8)  | 94 (95.9)                | 243 (94.2)             | 0.880   |
| Systemic Corticosteroid therapy  | 87 (22.7)   | 54 (55.1)                | 27 (10.5)              | 0.000** |
| Anti-malarial drug               | 93 (24.2)   | 22 (22.4)                | 62 (24.0)              | 0.843   |
| Parenteral anti-coagulant        | 134 (34.9)  | 52 (53.1)                | 77 (29.8)              | 0.004*  |
| ACE Inhibitors                   | 10 (2.6)    | 8 (8.2)                  | 1 (0.4)                | 0.111** |
| ARBs                             | 54 (14.1)   | 33 (33.7)                | 14 (5.4)               | 0.000** |
| Oxygen therapy                   | 20. (52.9)  | 95 (96.9)                | 92 (35.7)              | 0.000** |
| ICU support                      | 63 (16.4)   | 48 (49.0)                | 14 (5.4)               | 0.000** |
| Non-invasive ventilation         | 12 (3.1)    | 5 (5.1)                  | 6 (2.3)                | 0.736   |
| Invasive ventilation             | 16 (4.2)    | 15 (15.3)                | 1 (0.4)                | 0.000** |
| Inotropes/Vasopressors           | 21 (5.5)    | 15 (15.3)                | 6 (2.3)                | 0.000** |
| Prone position                   | 147 (38.3)  | 16 (16.3)                | 119 (46.1)             | 0.011** |
| CRRT                             | 36 (9.4)    | 18 (18.4)                | 16 (62)                | 0.015** |
| Complications                    |             |                          |                        |         |
| Septic shock                     | 37 (9.6)    | 33 (33.7)                | 4 (1.6)                | 0.000** |
| Anaemia                          | 21 (5.5)    | 7 (7.1)                  | 9 (3.5)                | 0.165   |
| Cardiac arrest                   | 19 (4.9)    | 19 (19.4)                | 0 (0.0)                | 0.000** |
| Pneumonia                        | 89 (23.2)   | 43 (43.9)                | 45 (15.5)              | 0.000** |
| ARDS                             | 93 (24.2)   | 85 (86.7)                | 7 (2.7)                | 0.000** |
| Acute kidney injury              | 16 (4.2)    | 12 (12.2)                | 3 (1.2)                | 0.002** |
| Time from illness onset to death or discharge in days mean (range) | 17.0 (12.0-21.0) | 9.0 (6.0-15.0) | 19.0 (15.25-22.0) | 0.000** |
| ICU length of stay in days mean (range) | 3.0 (1.0-7.0) | 7.0 (0.0-17.0) | 5.0 (1.0-10.0) | 0.004** |
| Time from admission into hospital to death or discharge in days mean (range) | 13.0 (7.0-16.0) | 14.0 (11.0-17.0) | 3.0 (1.0-9.0) | 0.015** |

‡ Percentages in parentheses
** Statistically significant

Discussions
In our study population nearly one third patients who had at least one kind of coexisting chronic disease. Cardiovascular disease, endocrine system disease, and respiratory system disease were the three most common coexisting chronic diseases. There were 219 patients who had no fever at admission. Additionally, 34 of the included COVID-19 patients did not exhibit any symptoms and were found to be positive only via the results of the SARS-CoV-2 PCR test. Most patients had systemic, respiratory, and digestive symptoms. Fever, dry cough, and fatigue were the three most common symptoms. The mortality rate in our study was lower than that indicated in a previous report but higher than that reported in another study. This heterogeneity is probably due to differences in the case inclusion criteria. However, our results were closer to the mortality rate indicated by official national statistics in China. Cumulative studies confirmed that older age was associated with poor outcomes in COVID-19 patients. In our study, older patients were prone to have severe COVID-19 symptoms and un-improvement, and were more likely to die in hospital. In previous findings in animal studies, older animals were shown to have stronger host innate immune responses to SARS-CoV infection. The unsatisfactory control of viral replication and more prolonged pro-inflammatory responses in older individuals due to age-dependent defects was found to lead to a marked decline in cell-mediated immune function and reduced humoral immune function, which potentially leads to poor outcomes. Fever, dizziness, muscle ache, expectoration, dyspnoea, and chest tightness at admission were
also found to influence patients' improvement in hospital. Dyspnoea and unconsciousness were the only two symptoms which were associated with mortality\(^{18,24}\).

A recent study reported the presence of SARS-CoV-2 nucleic acid fragments in the stool samples of patients with abdominal symptoms and suggested that SARS-CoV-2 might also be transmitted via the faecal–oral route\(^{21}\). In our study, approximately one third COVID-19 patients had digestive symptoms, especially nausea/vomiting and diarrhoea, which is more than was reported in a previous study\(^ {15}\). The digestive symptoms of most COVID-19 patients were mild, which seemed to be inconsistent with the pathogenicity of SARS-CoV-2. A possible explanation is that SARS-CoV-2 in the sputum of COVID-19 patients is transmitted to the digestive tract through swallowing. There, under the action of various digestive enzymes, the virulence of SARS-CoV-2 in the digestive tract is weakened and the virus is degraded into fragments that cause only mild digestive symptoms but not serious gastrointestinal damage.

**Conclusions**

This retrospective study of 384 cases of COVID-19 in Mugda Medical College and Hospital, Dhaka found that the epidemic was imported and transmitted within clusters. The disease typically presented as a viral pneumonia involving both lungs, with half of cases requiring oxygen therapy. Time from onset to admission and the high proportion of mild illness suggested patients presented early in their disease course. Moving forward, we hope to continue to deliver early and optimal care, limit community transmission, and tying the case fatality to the lower end of the known range.

**Acknowledgement**

We would like to thank all of our colleagues and other personnel of National Institute of Preventive and Social Medicine (NIPSOM), Mugda Medical College (MuMC) for their constructive cooperation. In addition, we would like to thank all of our co-authors for their valuable contribution for this work. We also acknowledge all of those helping hands, as without their valuable contribution this work couldn’t see the light of success.

**Limitations**

We did not approach patients to obtain additional history or biologic samples for laboratory measurement.

**Declarations**

**Funding:** No funding.

**Conflict of Interest:** No competing interests relevant to this study to disclose for all authors. Full forms submitted and on file for all authors.

**Ethical Approval:** All the procedures were conducted following the ethical guidelines of institution’s ethical committee (Institutional Review Board) at Mugda Medical College Hospital, Bangladesh (Memo No/MUMC/2020/597). The ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards will be followed wherever applicable.

**References**

1. Liang W, Liang H, Ou L, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients with COVID-19. *JAMA Intern Med.* Published online May 12, 2020. doi:10.1001/jamainternmed.2020.2033

2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020; 395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

3. United Nations Department of Economic and Social Affairs Population Dynamics. World population prospects 2019. Accessed April 6, 2020.

4. Chen Z, Peto R, Zhou M, et al; China Kadoorie Biobank (CKB) collaborative group.
Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies. *Lancet*. 2015;386(1002):1447-1456. doi:10.1016/S0140-6736(15)00340-2

5. Hossain I, Mullick AR, Khan MH, Akhtaruzzaman M, Rahman S, Tuhin SGN, et al. Impacts of Conventional Oxygen Therapy on COVID-19 Patient in Intensive Care Unit (ICU). J Med SciClin Res. 2020;08(08):183–9.

6. Hossain I, Khan MH, Ahmad SA, Akhtaruzzaman M, Tuhin SGN, Rahman S, et al. Characteristics of Inpatients’ Fatality Due to Covid-19 Pandemic: Experience from Mugda Medical College and Hospital, Dhaka, World J Adv Heal Care Res. 2020;4(5):11–5.

7. Hossain I, Mullick AR, Khan MH, Ahmad SA, Rahman S, Akhtaruzzaman M. Epidemiology of Coronavirus Disease: Past, Present, Future Prospects and Its Journey Towards Bangladesh. Int Med J. 2020;25(06):2517–29.

8. Institute for Health Metrics and Evaluation. GBD Compare/Viz Hub. Accessed April 6, 2020. https://vizhub.healthdata.org/gbd-compare/

9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775

10. Li Q, Guan X, Wu P et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; (published online Jan 29.) DOI:10.1056/NEJMoa2001316

11. Li Q, Guan X, Wu P et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; (published online Jan 29.) DOI:10.1056/NEJMoa2001316

12. Wang D, Hu B, Hu C et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020; (published online Feb 7.) DOI:10.1001/jama.2020.1585 10.

13. Chen N, Zhou M, Dong X et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020; 395: 507-513

14. Kalil AC, Metersky ML, Klompas M et al., Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63: e61-e111

15. World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. [cited 2020 Jan 24]. Available at: https://www.who.int/emergencies/diseases/2019-novel-coronavirus-2019/technical-guidance/laboratory-guidance

16. Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin, S., Jackson, C., Gamble, C., Horby, P. W., Nguyen-Van-Tam, J. S., M. G. (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. The BMJ, 369. https://doi.org/10.1136/bmj.m1985

17. Fei Zhou (2020) Clinical Course and Risk Factors for Mortality of Adult in Patients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. J Med Stud Res 3: 015.

18. Guan W.J., Ni Z.Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2002032
19. Smits S.L., de Lang A., van den Brand J.M., Leijten L.M., van Ijcken W.F., Eijkemans M.J.C., et al.: Exacerbated innate host response to SARS-CoV in aged non-human primates., PLoS Pathog. 2010; 6e1000756

20. Opal S.M., Girard T.D., Ely E.W.: The immune-pathogenesis of sepsis in elderly patients. Clin Infect Dis. 2005; 41: S504-S512

21. Chen T, Wu D, Chen H, et al: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091

22. Cortes Garcia M, Sierra Moros MJ, Santa-Olalla Peralta P, Hernandez-Barrera V, Jimenez-Garcia R, Pachon I: Clinical characteristics and outcomes of diabetic patients who were hospitalised with 2009 pandemic influenza A H1N1 infection. J Infect 2012; 64:218–224

23. Lippi G, Wong J, Henry BM: Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 2020; 130:304–309

24. Zhang H., Kang Z.J., Gong H.Y., Xu D., Wang J., Li Z. et al.: The digestive system is a potential route of 2019 nCoV infection: a bioinformatics analysis based on single-cell transcriptomes. (Preprint Posted Online January 31)2020 https://doi.org/10.1101/2020.01.30.927806.